Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
Stuart J. Connolly(Population Health Research Institute), Salim Yusuf(Population Health Research Institute), Gregory C. Flaker(University of Cape Town), John W. Eikelboom(Population Health Research Institute), Maria Grazia Franzosi(Goethe University Frankfurt), Jeff S. Healey(Population Health Research Institute), Janice Pogue(McMaster University), Patrick Commerford
Cited by 873
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study
|The Lancet|2005|2.9k
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
|New England Journal of Medicine|2017|2.4k
Subclinical Atrial Fibrillation and the Risk of Stroke
|New England Journal of Medicine|2012|2.1k